ERBB2 and cholangiocarcinoma: Because gemcitabine is one of the most significant first-line chemotherapeutic agents of CCA, we considered whether or not lapatinib has a synergistic repressive influence on the viability of HER2+ CCA cells when combined with gemcitabine.